Print

e-Therapeutics plc - Interim Results for the Six Months Ended 31 July 2012  
10/22/2012 9:21:45 AM

LONDON--(BUSINESS WIRE)--e-Therapeutics plc (AIM: ETX), the drug discovery and development company, today announces its interim results for the six months ended 31 July 2012.

Highlights

(*Events since the end of the period; **announced today)

Lead cancer drug ETS2101 enters clinic

• US phase I trial initiated in patients with brain cancer

• UK phase I trial begins in patients with solid tumours*

• First data expected Q4 2012; final results from brain cancer trial Q4 2013 and solid tumour trial Q1 2014**


//-->